J Clin Rheumatol 2021 Jan 22. Epub 2021 Jan 22.
From the Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany Servicio de Reumatología, Hospital Clínico de Valladolid, Valladolid Sección de Reumatología, Servicio de Medicina Interna, Complejo Asistencial de Palencia, Palencia, Spain.
The aims of this study were to describe the long-term retention rate of golimumab (GLM) treatment in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA) in real life, and to analyze determinants of discontinuation.
Methods: We conducted a single-center, medical records review of all patients with RA, PsA, and SpA on GLM treatment attending a large rheumatology department from 2010 to 2017. Times from start to end of GLM treatment were collected, as well as sociodemographic, clinical, and safety variables. Read More